Cargando…
Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis
BACKGROUND: Docetaxel, pemetrexed, erlotinib, and gefitinib are recommended as second-line treatment for advanced non-small cell lung cancer (NSCLC) with wild-type or unknown status for epidermal growth factor receptor (EGFR). However, the number of published randomized clinical trials (RCTs) on thi...
Autores principales: | Créquit, Perrine, Chaimani, Anna, Yavchitz, Amélie, Attiche, Nassima, Cadranel, Jacques, Trinquart, Ludovic, Ravaud, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662096/ https://www.ncbi.nlm.nih.gov/pubmed/29082855 http://dx.doi.org/10.1186/s12916-017-0954-x |
Ejemplares similares
-
Live cumulative network meta-analysis: protocol for second-line treatments in advanced non-small-cell lung cancer with wild-type or unknown status for epidermal growth factor receptor
por: Créquit, Perrine, et al.
Publicado: (2016) -
Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer
por: Créquit, Perrine, et al.
Publicado: (2016) -
Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study
por: Bafeta, Aïda, et al.
Publicado: (2012) -
Mapping of Crowdsourcing in Health: Systematic Review
por: Créquit, Perrine, et al.
Publicado: (2018) -
Impact of Reporting Bias in Network Meta-Analysis of Antidepressant Placebo-Controlled Trials
por: Trinquart, Ludovic, et al.
Publicado: (2012)